Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 + pembrolizumab vs physician’s choice in adjuvant TNBC after neoadjuvant KEYNOTE‑522 regimen without pCR
jRCT2061240081Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan in triple-negative breast cancer (TNBC) (2 arms), sponsored by Merck & Co. Primary endpoint: Invasive disease-free survival (iDFS). Started Jan 2025; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2061240081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240081.